| abstract |
Benzoindoline compounds of formula (I) that are alpha-AR/5-HT2C receptor antagonist, a process for their preparation and pharmaceutical compositions containing them are disclosed, wherein R1 and R2 together form a benzo ring optionally substituted by a halogen, alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, and R3 & R4 are represented by hydrogen, or R1, R2, R3 & R4 are as defined in the specification. These benzoindoline compounds are suitable for treating depression, anxiety, impulsive disorders, schizophrenia, Parkinson's disease, cognitive disorders, disorders of the libido and sexual dysfunctions, and sleep disorders. |